MMMichael A. Matter

Michael A. Matter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael A. Matter has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    oxLDL-induced aortic valve inflammation and calcification: opportunities for clinical translation

    by Yu-Jen Wang, Michael A Matter, Christian M Matter


  • Open Access

    2D echocardiography video to 3D heart shape reconstruction for clinical application

    by Fabian Laumer, Lena Rubi, Michael A. Matter, Stefano Buoso, Gabriel Fringeli, François Mach, Frank Ruschitzka, Joachim M. Buhmann, Christian M. Matter


  • Higher 1‐year mortality on rest days in patients with acute coronary syndromes and decompensated heart failure—A SPUM‐ACS sub‐study

    by Michael A. Matter, Alessandro Candreva, Barbara E. Stähli, Dik Heg, Roland Klingenberg, Lorenz Räber, Stephan Windecker, Nicolas Rodondi, David Nanchen, François Mach, et al.

    Background: Acute coronary syndromes (ACS) occurring on rest days have been associated with higher mortality, but the current literature remains inconsistent in this regard. This study included ACS patients presenting with acute decompensated heart failure (ADHF) investigating the relationship between time of coronary catheterization and outcomes.Methods: Analyses were performed from the prospective, multicentric Special Program University Medicine Acute Coronary Syndromes and Inflammation (SPUM‐ACS) Cohort. Patients were divided into two groups according to time of coronary catheterization on either workdays (Monday, 00:00 to Friday, 23:59) or rest days (Saturday, 00:00 to Sunday, 23:59 and public holidays). ADHF was defined by Killip Class III or IV upon presentation. Patients were followed over 1 year.Results: Out of 4787 ACS patients enrolled in the SPUM‐ACS Cohort, 207 (4.3%) presented with ADHF. 52 (25.1%) and 155 (74.9%) patients underwent coronary angiography on rest days or workdays, respectively. Baseline characteristics were similar among these groups. ACS patients with ADHF showed increased 1‐year mortality on rest days (34.6% vs. 17.4%, p‐value = 0.009). After correction for baseline characteristics, including the GRACE 2.0 Score, rest day presentation remained a significant predictor for 1‐year mortality (adjusted hazard ratio = 2.42 [95% confidence interval: 1.14–5.17], p‐value = 0.022).Conclusions: One‐year all‐cause mortality was high in ACS patients with ADHF and doubled for patients admitted on rest days. The present data support the association of a rest day effect and long‐term patient survival and indicate a need for further investigations.


  • Open Access

    Fully automated 4D cardiac modelling from 2D echocardiography for clinical applications

    by Fabian Laumer, Lena Rubi, Michael Matter, Stefano Buoso, Gabriel Fringeli, Francois Mach, Frank Ruschitzka, Joachim Buhmann, Christian Matter

    Transthoracic Echocardiography (TTE) is a crucial tool for assessing cardiac morphology and function quickly and non-invasively without ionizing radiation. However, the examination is subject to intra- and inter-user variability and recordings are often limited to 2D imaging and assessments of end-diastolic and end-systolic volumes. Current 3D TTE is time-consuming and provides lower image quality than 2D TTE. We have developed a novel, fully automated machine learning-based framework to generate a 4D (3D plus time) personalized model of the left ventricular (LV) blood pool. This digital twin was generated from specific 2D echocardiographic views employing deep neural networks, pre-trained on a synthetic dataset, and fine-tuned in a self-supervised manner using a novel optimization method for cross-sectional imaging data. This 4D model enabled detailed three dimensional analyses of LV systolic and diastolic function with high temporal resolution. Validation was performed on a multi-center dataset encompassing TTE exams of 144 patients with normal TTEs (controls) and 314 patients with acute myocardial infarction (AMI). LV volume measurements in controls derived from the digital twin showed a high correlation with the values from the clinical TTE reports (Pearson correlation coefficient of 0.7). In AMI patients, these novel biomarkers showed a high predictive value for survival (area under the curve (AUC) of 0.82 for 1-year all-cause mortality) and and excellent diagnostic value for infarct localisation and quantification, bearing the potential to improve diagnostic accuracy and risk assessment. Thus, our digital twin allows for fully automated robust LV shape analyses over time including contractility, relaxation, and regional wall motion abnormalities aiming at replacing expensive 3D imaging modalities with cheaper and more versatile 2D cardiac ultrasound.


  • Top Cited Papers
    Open Access

    Inflammation in acute myocardial infarction: the good, the bad and the ugly

    by Michael A Matter, Francesco Paneni, Peter Libby, Stefan Frantz, Barbara E Stähli, Christian Templin, Alessandro Mengozzi, Yu-Jen Wang, Thomas M Kündig, Lorenz Räber, et al.

    Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), i.e. the smouldering ember of low-grade inflammation persisting in the late phase after AMI. However, these studies have also taught us about potential risks of anti-inflammatory therapy after AMI, particularly related to impaired host defence. Recently, numerous smaller-scale trials have addressed the concept of targeting a deleterious flare of excessive inflammation in the early phase after AMI. Targeting different pathways and implementing various treatment regimens, those trials have met with varied degrees of success. Promising results have come from those studies intervening early on the interleukin-1 and -6 pathways. Taking lessons from such past research may inform an optimized approach to target post-AMI inflammation, tailored to spare ‘The Good’ (repair and defence) while treating ‘The Bad’ (smouldering RIR) and capturing ‘The Ugly’ (flaming early burst of excess inflammation in the acute phase). Key constituents of such a strategy may read as follows: select patients with large pro-inflammatory burden (i.e. large AMI); initiate treatment early (e.g. ≤12 h post-AMI); implement a precisely targeted anti-inflammatory agent; follow through with a tapering treatment regimen. This approach warrants testing in rigorous clinical trials.